Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives $4.50 Average PT from Brokerages

Heron Therapeutics, Inc. (NASDAQ:HRTX) has been assigned an average recommendation of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $4.50.

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Heron Therapeutics in a research note on Friday, January 9th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th.

Institutional Trading of Heron Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Clearline Capital LP raised its holdings in Heron Therapeutics by 1,033.1% during the 3rd quarter. Clearline Capital LP now owns 9,712,527 shares of the biotechnology company’s stock worth $12,238,000 after purchasing an additional 8,855,361 shares during the last quarter. Baker BROS. Advisors LP bought a new position in Heron Therapeutics during the third quarter worth $5,357,000. Citigroup Inc. raised its stake in Heron Therapeutics by 4,666.9% during the third quarter. Citigroup Inc. now owns 2,476,529 shares of the biotechnology company’s stock worth $3,120,000 after buying an additional 2,424,576 shares during the last quarter. Rubric Capital Management LP lifted its holdings in Heron Therapeutics by 8.9% in the third quarter. Rubric Capital Management LP now owns 29,100,728 shares of the biotechnology company’s stock valued at $36,667,000 after buying an additional 2,387,225 shares during the period. Finally, Velan Capital Investment Management LP boosted its position in Heron Therapeutics by 25.3% during the third quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock valued at $11,029,000 after acquiring an additional 1,766,546 shares during the last quarter. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $1.15 on Thursday. Heron Therapeutics has a 52 week low of $1.00 and a 52 week high of $2.68. The company has a market capitalization of $210.86 million, a PE ratio of -12.78 and a beta of 1.25. The company has a debt-to-equity ratio of 19.89, a quick ratio of 1.78 and a current ratio of 2.56. The company has a 50 day moving average price of $1.34 and a two-hundred day moving average price of $1.30.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.